Gordian Group

Gordian Biotechnology is a San Francisco-based drug discovery company pioneering an in vivo therapeutic screening platform to address diseases of aging. The company's proprietary technology enables the simultaneous testing of thousands of genetic therapies within a single animal, bypassing the limitations of traditional cell-culture-based discovery. By using 'mosaic' animal models, Gordian can observe how potential treatments affect diseased tissues in their natural, complex environment at single-cell resolution. Their current pipeline and research focus include high-prevalence age-related conditions such as non-alcoholic steatohepatitis (NASH), heart failure, and osteoarthritis. Gordian has established significant industry collaborations, including a partnership with AstraZeneca to identify novel targets for heart failure and chronic kidney disease.